

ESPS Peer-review Report

Name of Journal: World Journal of Clinical Oncology

ESPS Manuscript NO: 8888

Title: Incidence and Management of Ziv-Aflibercept Related Toxicities in Colorectal Cancer

Reviewer code: 00374038

Science editor: Wen, Ling-Ling

Date sent for review: 2014-01-11 13:36

Date reviewed: 2014-01-11 19:37

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input checked="" type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This review addresses the toxicities in clinical trials using Ziv for the treatment of mCRC, and provides recommendations for toxicity management. In general, this manuscript is well written.

Comments: In addition to symptomatic treatment for the toxicity of Ziv, the authors should discuss toxicity management in related to the molecular mechanisms of Ziv-associated side effects.

ESPS Peer-review Report

Name of Journal: World Journal of Clinical Oncology

ESPS Manuscript NO: 8888

Title: Incidence and Management of Ziv-Aflibercept Related Toxicities in Colorectal Cancer

Reviewer code: 00504462

Science editor: Wen, Ling-Ling

Date sent for review: 2014-01-11 13:36

Date reviewed: 2014-01-13 08:02

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Dear Sir, Your information is of great value as it seems that the review do not contemplate only the benefit but focus on the side effects too. The drug you are describing is very interesting at it might become part of the conventional treatment for the metastatic colon cancer. However, before it will be published, there are some corrections you must do: a) In the page 4, you wrote "The types of cancer of these 32 patients were as follows: 8 pancreatic, 3 cholangiocarcinoma, 3 gastric, 5 breast, 4 ovarian and 7 other malignancies. In this study, 5 partial responses were noted in the pancreatic, cholangiocarcinoma and colorectal cancers", but.... How many colorectal cancer patients were included? b) Is it possible for you to summarize the side effects grades, and their meaning in a table for the readers who are not aware of them? c) Is it possible to compare the side effects of this drug with others drugs with the same mechanism of action, like bevacizumab? Otherwise I hope to hear from you soon, in order to publish your manuscript.